Some reassuring news for patients taking GLP-1 receptor agonists: Concerns that the drugs may cause retinopathy may be overblown.

A new analysis of nearly 160,000 people with diabetes taking four different GLP-1 medications for at least a year has found no increased risk for diabetic retinopathy associated with the drugs.

Andrew J. Barkmeier, MD

“We found no difference in the risk of sight-threatening retinopathy between GLP-1 agents among adults with type 2 diabetes and moderate cardiovascular risk, and this supports choosing the most appropriate agent for patients without consideration of potential difference in diabetic retinopathy complications,” Andrew J. Barkmeier, MD, a retina specialist at Mayo Clinic in Rochester, Minnesota, reported at the American Society of Retina Specialis

See Full Page